Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Raiders11on Apr 15, 2021 8:32pm

190 Views

Post# 33008462

Short report as of march 31

Mar 31, 2021Shares Shorted: 623,752 Net Change: -14,114,046 Mar 15, 2021Shares Shorted: 14,737,798 Net Change: 14,480,718 Feb 28, 2021Shares Shorted: 257,080 Net Change: 123,363 Feb 15, 2021Shares Shorted: 133,717 Net Change: 25,437 Jan 31, 2021Shares Shorted: 108,280 Net Change: 0 Jan 15, 2021Shares Shorted: 108,280 Net Change: 0 Dec 31, 2020Shares Shorted: 108,280 Net Change: 0 Dec 15, 2020Shares Shorted: 108,280 Net Change: 0 Nov 30, 2020Shares Shorted: 108,280 Net Change: 0 Nov 15, 2020Shares Shorted: 108,280

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December